Collegium Pharmaceutical, Inc. Shareholders' Equity
Collegium Pharmaceutical, Inc. (COLL) had Shareholders' Equity of $311.91 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $311.91M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $312.42M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $301.68M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $274.81M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $311.91M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $312.42M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $301.68M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $274.81M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $232.21M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $234.43M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $228.84M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $234.28M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $216.58M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $222.17M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $195.43M 10-K · filed 2026-02-26 |
| 2023-09-30 | $178.87M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $200.81M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $179.73M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $194.84M 10-K · filed 2026-02-26 |
| 2022-09-30 | $197.19M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $197.61M 10-Q · filed 2023-11-07 |
| 2022-03-31 | $196.08M 10-Q · filed 2023-11-07 |
| 2021-12-31 | $202.93M 10-K · filed 2025-02-27 |
| 2021-09-30 | $251.09M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $253.07M 10-Q · filed 2022-11-03 |
| 2021-03-31 | $170.03M 10-Q · filed 2022-11-03 |
| 2020-12-31 | $186.03M 10-K · filed 2024-02-22 |
| 2020-09-30 | $172.69M 10-Q · filed 2021-11-04 |
| 2020-06-30 | $155.77M 10-Q · filed 2021-11-04 |
| 2020-03-31 | $141.06M 10-Q · filed 2021-11-04 |
| 2019-12-31 | $87.43M 10-K · filed 2023-02-23 |
| 2019-09-30 | $84.26M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $85.82M 10-Q · filed 2020-11-05 |
| 2019-03-31 | $86.35M 10-Q · filed 2020-11-05 |
| 2018-12-31 | $91.58M 10-K · filed 2022-02-24 |
| 2018-09-30 | $70.78M 10-Q · filed 2019-11-06 |
| 2018-06-30 | $82.68M 10-Q · filed 2019-11-06 |
| 2018-03-31 | $90.82M 10-Q · filed 2019-11-06 |
| 2017-12-31 | $104.08M 10-Q · filed 2019-11-06 |
| 2017-09-30 | $96.27M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $95.51M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $114.37M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $134.91M 10-K · filed 2018-03-07 |
| 2016-09-30 | $74.33M 10-Q · filed 2016-11-10 |
| 2016-06-30 | $98.66M 10-Q · filed 2016-08-11 |
| 2016-03-31 | $121.74M 10-Q · filed 2016-05-11 |
| 2015-12-31 | $85.07M 10-K · filed 2017-03-10 |
| 2015-09-30 | $93.56M 10-Q · filed 2015-11-12 |
| 2015-06-30 | $102.42M 10-Q · filed 2015-08-12 |
| 2015-03-31 | -$85.22M 10-Q/A · filed 2015-07-17 |
| 2014-12-31 | -$89.35M 10-K · filed 2016-03-18 |
| 2013-12-31 | -$68.22M 10-K · filed 2016-03-18 |
| 2012-12-31 | -$61.40M 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |